B. Oza

Adaptive immunity and neutralizing antibodies against SARS-CoV-2 variants of concern following vaccination in patients with cancer: The CAPTURE study

Robin L. Jones, L. Pickering, C. Swanton, 2021, Nature Cancer.

Adjuvant Sorafenib for Renal Cell Carcinoma at Intermediate or High Risk of Relapse: Results From the SORCE Randomized Phase III Intergroup Trial.

E. Frangou, M. Stockler, M. Parmar, 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

RAMPART: A phase III multi-arm multi-stage trial of adjuvant checkpoint inhibitors in patients with resected primary renal cell carcinoma (RCC) at high or intermediate risk of relapse

E. Frangou, M. Stockler, M. Parmar, 2021, Contemporary clinical trials.

RAMPART: A model for a regulatory-ready academic-led phase III trial in the adjuvant renal cell carcinoma setting.

E. Frangou, M. Stockler, T. Choueiri, 2021, Contemporary clinical trials.

Adaptive immunity and neutralizing antibodies against SARS-CoV-2 variants of concern following vaccination in patients with cancer: The CAPTURE study

Lucy J. Holt, Robin L. Jones, L. Pickering, 2021, Nature Cancer.

Primary efficacy analysis results from the SORCE trial (RE05): Adjuvant sorafenib for renal cell carcinoma at intermediate or high risk of relapse: An international, randomised double-blind phase III trial led by the MRC CTU at UCL

E. Frangou, M. Stockler, J. Bellmunt, 2019, Annals of Oncology.

External Validation of the 2003 Leibovich Prognostic Score in Patients Randomly Assigned to SORCE, an International Phase III Trial of Adjuvant Sorafenib in Renal Cell Cancer

E. Frangou, M. Stockler, M. Parmar, 2022, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.